Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

Positive topline data from phase IIb study of ARQ-154 in scalp and body psoriasis

Nov. 24, 2020

Promore reports phase IIb data on ropocamptide for venous leg ulcers

Nov. 20, 2020

JAK inhibitor prodrugs discovered at Theravance Biopharma

Nov. 19, 2020

Tofacitinib demonstrates long-term safety and efficacy in refractory dermatomyositis

Nov. 17, 2020

Phase III trial shows efficacy and safety of intravenous immunoglobulin in treating dermatomyositis

Nov. 17, 2020

Designed Cells, Chungbuk National University patent stem cell-derived exosome-rich culture medium

Nov. 17, 2020

Phase II data presented for SHR-1314 in patients with plaque psoriasis

Nov. 16, 2020

Pfizer announces positive data from phase III JADE REGIMEN study of abrocitinib

Nov. 12, 2020

Arena reports topline phase IIb results with etrasimod in atopic dermatitis

Nov. 10, 2020

HT-005 reduces skin plaque severity in cutaneous lupus erythematosus mouse model

Nov. 4, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 22, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...